Which Tablets Help, and Which May Not
Reviewed by CDE Mehandi Sharma · Updated
In Type 2 diabetes, a tablet is judged mainly by how far it lowers your blood sugar. In LADA there is a second question: what does it do to the insulin-making cells you have left?
| Medicine | Position in LADA |
|---|---|
| Metformin | Commonly used; evidence in LADA is limited but it is not thought to harm beta cells |
| Sulfonylureas | Generally discouraged — linked to faster loss of insulin production |
| DPP-4 inhibitors | The most promising tablet group; some evidence of protecting beta-cell function |
| Insulin | Needed by most people eventually, and may be started early by choice |
The sulfonylurea point is the one that most often changes a prescription. These tablets — glimepiride, gliclazide, glibenclamide and others — work by driving your beta cells to release more insulin. In LADA those cells are already under immune attack, and studies have found faster decline in insulin production and an earlier move to injections in people taking them.
This is a genuine tension in India, because sulfonylureas are among the cheapest and most widely stocked diabetes tablets available.
There is one further caution. SGLT2 inhibitors carry a risk of ketoacidosis when insulin levels are low, so anyone with LADA taking one needs to know how to check for ketones.